ELQ-300
ELQ-300 is an experimental antimalarial medication.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
ELQ-300 is an experimental antimalarial medication. It is the first entry in a new class of antimalarials known as 4-quinolone-3-diarylethers. ELQ-300 acts as an inhibitor of the mitochondrial cytochrome bc 1 complex (complex III in the electron transport chain) - A mechanism shared with some of the most potent fungicides known, the strobilurins.
In preclinical studies with mice, ELQ-300 was found to be highly active against Plasmodium falciparum and Plasmodium vivax at all life cycle stages that play a role in the transmission of malaria, and to have good oral bioavailability. Due to issues with crystallization, ELQ-300 was turned into a prodrug known as ELQ-331.
ELQ-331 and two other similar drug candidates are currently in development.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1343831831 under CC BY-SA 4.0; modifications have been made.